Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Introduction: Biomarkers in Breast Cancer

June 17th 2015

Holli Dilks on Molecular Profiling

June 12th 2015

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Potential Bevacizumab Biomarker Identified in Ovarian Cancer

June 10th 2015

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

Rucaparib Response Rate Exceeds 80% in BRCA-mutant Ovarian Cancer

June 9th 2015

Treatment with the PARP inhibitor rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer

Largest-Ever Precision Medicine Oncology Trial Ready for Launch

June 1st 2015

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.

Off-Label Access to Targeted Therapies Offered Through ASCO's First-Ever Clinical Trial

June 1st 2015

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Proteoglycan Assay Shows Potential as Adjunct to PSA Measurement

May 18th 2015

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Siteman Cancer Center Houses Broad Research Program

May 15th 2015

Venetoclax Breakthrough Designation, Zarxio Legal Update, and More

May 15th 2015

Taking Lung Cancer Care into the Precision Medicine Era

May 5th 2015

The recent approval of nivolumab in the nonâ€“small cell lung cancer setting marks a unique shift in the treatment landscape of this malignancy, one that harnesses the patient's own immune system to target the tumors. However, there are challenges in using these agents.